<DOC>
	<DOCNO>NCT01913483</DOCNO>
	<brief_summary>The primary objective study demonstrate anticoagulation bivalirudin result few major bleeding complication compare unfractionated heparin ( UFH ) subject undergoing peripheral endovascular intervention ( PEI ) . The secondary objective identify potential benefit bivalirudin therapy clinically important event death , myocardial infarction ( MI ) , stroke and/or transient ischemic attack ( TIA ) , amputation , unplanned repeat revascularization ( URV ) , minor bleeding , well potential economic benefit may result improved clinical outcome .</brief_summary>
	<brief_title>ENDOvascular Interventions With AngioMAX : The ENDOMAX Trial</brief_title>
	<detailed_description />
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<criteria>Subjects ≥ 18 year age Must undergo one follow PEI procedure : Carotid artery stenting ( approximately 33 % study sample ) Lower Extremity Interventions ( LEI ) Critical Limb Ischemia ( CLI ) ( approximately 33 % study sample ) LEI claudication ( approximately 33 % study sample ) Provide write informed consent prior studyspecific procedure perform Any known contraindication use bivalirudin UFH Acute limb ischemia Planned amputation regardless outcome PEI Dialysis dependent Weight le 38 kilogram ( kg ) 202 kg History bleeding diathesis severe hematological disease History intracranial : mass , aneurysm , arteriovenous malformation hemorrhage Gastrointestinal genitourinary bleeding within 30 day prior randomization Any surgery ( exclude punch shave skin biopsy ) within 30 day prior randomization Concomitant percutaneous coronary intervention ( PCI ) Any percutaneous coronary , endovascular , structural heart disease procedure within 30 day prior randomization International normalize ratio ( INR ) &gt; 1.7 within 24 hour ( h ) prior index procedure Administration therapeutic dos UFH within 30 minute ( min ) prior index procedure ( low dose [ ≤2000 unit ( U ) ] heparin permit diagnostic angiogram prior intervention ) Administration enoxaparin within 8 hour ; low molecular weight heparin ( LMWHs ) fondaparinux within 24 hour ; oral antiXa antithrombin agent within 48 hour ; thrombolytic , glycoprotein inhibitor ( GPI ) , warfarin within 72 hour prior index procedure Severe contrast allergy premedicated Procedures perform radial access intend primary access site index procedure Known suspect pregnant woman nurse mother Previous enrollment study ( MDCOBIV1203 ) Participation investigational drug device trial within 30 day prior randomization Subjects , reason , deem investigator inappropriate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>